Vendor review
Laicuinuo LCN reviews
Laicuinuo LCN reviews from 45 independent lab tests (Retatrutide, Tirzepatide and GHK-Cu): grade A, purity and fill accuracy. Is Laicuinuo LCN legit? See what its vials showed.
What the lab tests show
45 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Sep 30, 2026 | Retatrutide | 99.9 % | 9.99 mg of 10 mg (0 %) | Pass | View |
| Sep 30, 2026 | Retatrutide | 99.9 % | 9.99 mg of 10 mg (0 %) | Pass | View |
| Sep 24, 2026 | BPC-157 | 5 mg | Fail | View | |
| Sep 24, 2026 | Tirzepatide | 30 mg | Fail | View | |
| Sep 24, 2026 | GHK-Cu | 99.9 % | 53.8 mg of 100 mg (-46 %) | Pass | View |
| Sep 16, 2026 | Tirzepatide | 99.9 % | 17.6 mg of 30 mg (-41 %) | Pass | View |
| Sep 15, 2026 | GHK-Cu | 99.7 % | 107 mg of 100 mg (7 %) | Pass | View |
| Sep 5, 2026 | Retatrutide | 20 mg | Fail | View | |
| Sep 5, 2026 | Tesamorelin | 10 mg | Fail | View | |
| Sep 4, 2026 | GHK-Cu | 99.9 % | 45.1 mg of 50 mg (-10 %) | Pass | View |
| Aug 25, 2026 | Retatrutide | 20 mg | Fail | View | |
| Aug 25, 2026 | Retatrutide | 10 mg | Fail | View | |
| Aug 3, 2026 | Tesamorelin | 10 mg | Fail | View | |
| Aug 2, 2026 | Retatrutide | 99.9 % | 40.1 mg of 20 mg (101 %) | Pass | View |
| Jul 20, 2026 | Tirzepatide | 10 mg | Fail | View | |
| Jul 20, 2026 | Retatrutide | 99.9 % | 18.2 mg of 10 mg (82 %) | Pass | View |
| Jul 13, 2026 | Retatrutide | 99.9 % | 22.3 mg of 20 mg (12 %) | Pass | View |
| Jul 13, 2026 | Tesamorelin | 99.9 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Jul 10, 2026 | Retatrutide | 20 mg | Fail | View | |
| Jun 2, 2026 | Retatrutide | 20 mg | Fail | View | |
| May 11, 2026 | Retatrutide | 20 mg | Fail | View | |
| May 5, 2026 | Tirzepatide | 99.9 % | 15.9 mg of 30 mg (-47 %) | Pass | View |
| Mar 19, 2026 | Retatrutide | 99.9 % | 18.5 mg of 20 mg (-8 %) | Pass | View |
| Mar 19, 2026 | Retatrutide | 99.9 % | 8.75 mg of 10 mg (-13 %) | Pass | View |
| Mar 5, 2026 | Tirzepatide | 99.9 % | 20.6 mg of 20 mg (3 %) | Pass | View |
| Mar 2, 2026 | Tirzepatide | 99.9 % | 20.9 mg of 20 mg (4 %) | Pass | View |
| Mar 2, 2026 | Tirzepatide | 99.9 % | 15.7 mg of 15 mg (5 %) | Pass | View |
| Mar 2, 2026 | GHK-Cu | 99.9 % | 78.7 mg of 100 mg (-21 %) | Pass | View |
| Mar 2, 2026 | Tesamorelin | 99.9 % | 5.08 mg of 5 mg (2 %) | Pass | View |
| Mar 2, 2026 | CJC-1295 | 99.9 % | 5.22 mg of 5 mg (4 %) | Pass | View |
| Feb 20, 2026 | CJC-1295 | 10 mg | Fail | View | |
| Feb 20, 2026 | Retatrutide | 99.7 % | 11.2 mg of 10 mg (12 %) | Pass | View |
| Jan 7, 2026 | Tirzepatide | 99.7 % | 21.7 mg of 20 mg (9 %) | Pass | View |
| Dec 6, 2025 | Tirzepatide | 99.95 % | 34.6 mg of 20 mg (73 %) | Pass | View |
| Nov 18, 2025 | Retatrutide | 99.76 % | 5.1 mg of 5 mg (2 %) | Pass | View |
| Oct 24, 2025 | Tirzepatide | 99.6 % | 4.98 mg of 5 mg (0 %) | Pass | View |
| Oct 24, 2025 | Tirzepatide | 99.8 % | 32.09 mg of 30 mg (7 %) | Pass | View |
| Oct 23, 2025 | Tirzepatide | 99.95 % | 30.6 mg of 30 mg (2 %) | Pass | View |
| Oct 23, 2025 | BPC-157 | 99.58 % | 5.54 mg of 10 mg (-45 %) | Pass | View |
| Oct 23, 2025 | CJC-1295 | 99.75 % | 10.3 mg of 10 mg (3 %) | Pass | View |
| Oct 17, 2025 | Retatrutide | 99.74 % | 9.68 mg of 10 mg (-3 %) | Pass | View |
| Oct 3, 2025 | Tirzepatide | 99.82 % | 10 mg of 10 mg (0 %) | Pass | View |
| Sep 30, 2025 | Tirzepatide | 99.93 % | 29.8 mg of 30 mg (-1 %) | Pass | View |
| Sep 10, 2025 | Retatrutide | 99.95 % | 10.8 mg of 10 mg (8 %) | Pass | View |
| Sep 10, 2025 | BPC-157 | 99.94 % | 9.06 mg of 10 mg (-9 %) | Pass | View |
What Laicuinuo LCN sells
No current listings on record.
About Laicuinuo LCN
Finnrick has tested 45 samples from Laicuinuo LCN across 6 products.